Clinical trial

Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer

NCT03503344

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Apalutamide Normalized identity: apalutamideView linked drug · Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention Stereotactic Body Radiation Therapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2019-12-17

PhasePHASE2

Conditions

Castration Levels of Testosteroneunresolved

Castration-Resistant Prostate Carcinomaverified · MONDO: castration-resistant prostate carcinoma

PSA Progressionunresolved

Stage IV Prostate Adenocarcinoma AJCC v7unresolved

Interventions

ApalutamideDRUG · verified · RxNorm: apalutamide

Stereotactic Body Radiation TherapyRADIATION

Sponsors & collaborators

University of California, San Franciscolead sponsor

Janssen Pharmaceuticalscollaborator

Mapped research locations

San FranciscoCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03503344 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.